Skip to main content
Annovis Bio, Inc. logo

Annovis Bio, Inc. — Investor Relations & Filings

Ticker · ANVS ISIN · US03615A1088 LEI · 549300IFBVI51FN3NJ32 US Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2023-01-20 Director's Dealing
Country US United States of America
Listing US ANVS

About Annovis Bio, Inc.

https://www.annovisbio.com/

Annovis Bio, Inc. is a clinical-stage drug platform company that develops therapies for neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead product candidate, buntanetap, is a translational inhibitor designed to halt the death of nerve cells by targeting the synthesis of multiple neurotoxic proteins. The company's therapeutic approach aims to restore nerve cell function, with the goal of improving cognitive and motor abilities in patients suffering from neurodegeneration.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-20 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-20 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-20 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-20 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions that the company posted a presentation to its website for use in meetings with investors and others, and that the presentation is attached as Exhibit 99.1. The document does not contain financial statements or detailed financial analysis itself but rather references a presentation. The length of the document is 3545 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, a document that announces or attaches a presentation for investors without containing the full report or detailed financial data should be classified as an Investor Presentation (IP).
2023-01-06 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.